Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, has provided a strategic update on its operational orientation. The company's focus remains on sustainable, technology-driven growth in the international MedTech market, concentrating on developing innovative medical devices and translational research for severe respiratory diseases, particularly ventilator-associated pneumonia (VAP).
Over the past two years, Viromed has developed two novel cold plasma medical devices: ViroCAP®, an innovative cold plasma device for medical wound healing, and PulmoPlas®, a globally unique cold plasma system for applications in pneumology and respiratory tract infections. The company attributes particular importance to the PulmoPlas® platform, which forms the basis for future scaling across multiple medical indication areas. According to its own assessment, Viromed will play a significant role in the global fight against pathogenic germs in the coming years, especially with PulmoPlas®.
In the research domain, Viromed has established a high-performance scientific consortium comprising Hannover Medical School (MHH), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, and the Leibniz Institute in Jena. This network brings together international top-level expertise in infectiology, pneumology, and translational research, enabling the development of novel therapeutic approaches for upper and lower respiratory tract diseases. Comprehensive publication of results by MHH and HZI is expected at the end of January 2026.
For further technological development, Viromed works closely with Relyon Plasma, a subsidiary of TDK. Additionally, international partnerships in Europe, Korea, and Turkey have been established to support future market entry and underscore the global relevance of the technology. As a result of the strategic focus on research, development, and international market structures, longer innovation cycles arise. Viromed deliberately refrains from communicating short-term operational interim updates, instead reporting substantial and relevant milestones for long-term sustainable corporate development.
Viromed has also successfully overcome new stringent regulatory hurdles for the approval of ViroCAP® over the past 18 months, and market acceptance and demand for ViroCAP® are already very high. The company's corporate strategy is geared toward long-term value generation, with research and development programs consistently aligned with medical benefit, clinical relevance, and sustainable market potential.
Viromed Medical AG specializes in the development, manufacture, and distribution of medical products, focusing on cold plasma technology via its wholly owned subsidiary Viromed Medical GmbH. The company pursues the goal of further advancing cold plasma technology in medicine and realizing corresponding growth potential. More information is available at www.viromed-medical-ag.de.
